Bogart Wealth LLC Has $7.09 Million Position in Boston Scientific Corporation $BSX

Key Points

• Bogart Wealth LLC increased its stake in Boston Scientific Corporation by 4.9%, now holding 65,991 shares valued at approximately $7.09 million.
• A variety of hedge funds are modifying their positions in Boston Scientific, with significant increases from firms such as Evermay Wealth Management and Calamos Wealth Management.
• Boston Scientific reported a quarterly earnings per share (EPS) of $0.75, exceeding analyst expectations of $0.72, while revenue rose to $5.06 billion, reflecting a 22.8% increase year-over-year.

Bogart Wealth LLC grew its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,991 shares of the medical equipment provider's stock after purchasing an additional 3,070 shares during the period. Bogart Wealth LLC's holdings in Boston Scientific were worth $7,088,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $32,000. Evermay Wealth Management LLC boosted its stake in shares of Boston Scientific by 190.9% in the 2nd quarter. Evermay Wealth Management LLC now owns 1,219 shares of the medical equipment provider's stock valued at $131,000 after purchasing an additional 800 shares in the last quarter. Stephens Inc. AR raised its holdings in Boston Scientific by 10.7% in the 2nd quarter. Stephens Inc. AR now owns 10,846 shares of the medical equipment provider's stock valued at $1,165,000 after buying an additional 1,046 shares during the last quarter. Balboa Wealth Partners bought a new position in Boston Scientific in the 2nd quarter valued at approximately $216,000. Finally, Calamos Wealth Management LLC raised its holdings in Boston Scientific by 2.9% in the 2nd quarter. Calamos Wealth Management LLC now owns 101,786 shares of the medical equipment provider's stock valued at $10,933,000 after buying an additional 2,864 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research reports. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Raymond James Financial lifted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, October 11th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, BTIG Research lifted their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $120.71.

Boston Scientific Stock Performance

Shares of BSX stock opened at $99.20 on Monday. The firm has a market capitalization of $146.99 billion, a PE ratio of 59.05, a price-to-earnings-growth ratio of 2.39 and a beta of 0.61. The firm has a fifty day simple moving average of $101.29 and a two-hundred day simple moving average of $101.77. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last quarter. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.